857130 | 18:1 Lyso PA
1-oleoyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt)
18:1 Lyso PA
1-oleoyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt)
- Cell Proliferation
- Inhibition of differentiation (neuroblastoma cells, myoblasts)
- Platelet aggregation
- Smooth muscle contraction
- Neurotransmitter release
- Stress fibre formation/cell rounding/neurite retraction
- Cell-surface-fibronectin binding
- Tumor cell invasion
- Chemotaxis (dictyostelium amoebae)
- Cl--mediated membrane depolarization (fibroblasts)
- Inhibition of connexin 43 based cell-cell communication
- Increased tight junction permeability (brain endothelial cells)
CAS Registry Number is a Registered Trademark of the American Chemical Society
1-(9Z-octadecenoyl)-sn-glycero-3-phosphate (sodium salt)
PA(18:1(9Z)/0:0)
18:1 LPAo-LPA
110681
Key CC, Bishop AC, Wang X, Zhao Q, Chen GY, Quinn MA, Zhu X, Zhang Q, Parks JS. Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake. J Lipid Res. 2020 May 19:jlr.RA120000760. doi: 10.1194/jlr.RA120000760. Epub ahead of print. PMID: 32430316.
PubMed ID: 32430316Cho YJ, Choi SH, Lee R, Hwang H, Rhim H, Cho IH, Kim HC, Lee JI, Hwang SH, Nah SY. Ginseng Gintonin Contains Ligands for GPR40 and GPR55. Molecules. 2020 Mar 2;25(5):1102. doi: 10.3390/molecules25051102. PMID: 32121640; PMCID: PMC7179172.
PubMed ID: 32121640Gupta VK, Jaiswara PK, Sonker P, Rawat SG, Tiwari RK, Kumar A. Lysophosphatidic acid promotes survival of T lymphoma cells by altering apoptosis and glucose metabolism. Apoptosis. 2020 Feb;25(1-2):135-150. doi: 10.1007/s10495-019-01585-1. PMID: 31867678.
PubMed ID: 31867678Yamada H, Mizuno S, Honda S, Takahashi D, Sakane F. Characterization of α-synuclein N-terminal domain as a novel cellular phosphatidic acid sensor. FEBS J. 2019 Nov 13. doi: 10.1111/febs.15137. [Epub ahead of print]
PubMed ID: 31722116Antoku S, Wu W, Joseph LC, Morrow JP, Worman HJ, Gundersen GG. ERK1/2 Phosphorylation of FHOD Connects Signaling and Nuclear Positioning Alternations in Cardiac Laminopathy. Dev Cell. 2019 Dec 2;51(5):602-616.e12. doi: 10.1016/j.devcel.2019.10.023.
PubMed ID: 31794718Antoku S, Wu W, Joseph LC, Morrow JP, Worman HJ, Gundersen GG. ERK1/2 Phosphorylation of FHOD Connects Signaling and Nuclear Positioning Alternations in Cardiac Laminopathy. Dev Cell. 2019 Dec 2;51(5):602-616.e12. doi: 10.1016/j.devcel.2019.10.023.
PubMed ID: 31794718Ciesielska A, Hromada-Judycka A, Ziemlińska E, Kwiatkowska K. Lysophosphatidic acid up-regulates IL-10 production to inhibit TNF-α synthesis in Mϕs stimulated with LPS. J Leukoc Biol. 2019 Jul 23. doi: 10.1002/JLB.2A0918-368RR. [Epub ahead of print]
PubMed ID: 31335985Mahajan D, Tie HC, Chen B, Lu L. Dopey1-Mon2 complex binds to dual-lipids and recruits kinesin-1 for membrane trafficking. Nat Commun. 2019 Jul 19;10(1):3218. doi: 10.1038/s41467-019-11056-5.
PubMed ID: 31324769Tabbai S, Moreno-Fernández RD, Zambrana-Infantes E, Nieto-Quero A, Chun J, García-Fernández M, Estivill-Torrús G, Rodríguez de Fonseca F, Santín LJ, Oliveira TG, Pérez-Martín M, Pedraza C. Effects of the LPA1 Receptor Deficiency and Stress on the Hippocampal LPA Species in Mice. Front Mol Neurosci. 2019 Jun 11;12:146. doi: 10.3389/fnmol.2019.00146. eCollection 2019.
PubMed ID: 31244601Mathew D, Kremer KN, Strauch P, Tigyi G, Pelanda R, Torres RM. LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling. Front Immunol. 2019 May 28;10:1159. doi: 10.3389/fimmu.2019.01159. eCollection 2019.
PubMed ID: 31231367Angkawijaya AE, Nguyen VC, Nakamura Y. Lysophosphatidic acid acyltransferases 4 and 5 are involved in glycerolipid metabolism and nitrogen starvation response in Arabidopsis. New Phytol. 2019 Jun 18. doi: 10.1111/nph.16000. [Epub ahead of print]
PubMed ID: 31211859Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, Ono Y, Shinjo Y, Ishida S, Arang N, Kawakami K, Gutkind JS, Aoki J, Russell RB. Illuminating G-Protein-Coupling Selectivity of GPCRs. Cell. 2019 Jun 13;177(7):1933-1947.e25. doi: 10.1016/j.cell.2019.04.044. Epub 2019 May 31.
PubMed ID: 31160049Kommineni N, Mahira S, Domb AJ, Khan W. Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects. Pharmaceutics. 2019 Mar 25;11(3). pii: E141. doi: 10.3390/pharmaceutics11030141.
PubMed ID: 30934535Choi SH, Kim HJ, Cho HJ, Park SD, Lee NE, Hwang SH, Rhim H, Kim HC, Cho IH, Nah SY. Gintonin-mediated release of astrocytic vascular endothelial growth factor protects cortical astrocytes from hypoxia-induced cell damages. J Ginseng Res. 2019 Apr;43(2):305-311. doi: 10.1016/j.jgr.2018.05.006. Epub 2018 May 31.
PubMed ID: 30976168Reinink P, Souter MNT, Cheng TY, van Gorkom T, Lenz S, Kubler-Kielb J, Strle K, Kremer K, Thijsen SFT, Steere AC, Godfrey DI, Pellicci DG, Moody DB, Van Rhijn I. CD1b presents self and Borrelia burgdorferi diacylglycerols to human T cells. Eur J Immunol. 2019 Mar 10. doi: 10.1002/eji.201847949. [Epub ahead of print]
PubMed ID: 30854633Kim HY, Jin H, Bae J, Choi HK. Metabolic and lipidomic investigation of the antiproliferative effects of coronatine against human melanoma cells. Sci Rep. 2019 Feb 28;9(1):3140. doi: 10.1038/s41598-019-39990-w.
PubMed ID: 30816283Kim B, Pena CD, Auguste DT. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1-/FOXM1+ Triple Negative Breast Cancer Cells. Mol Pharm. 2019 Mar 29. doi: 10.1021/acs.molpharmaceut.8b01065. [Epub ahead of print]
PubMed ID: 30883132Kim B, Pena CD, Auguste DT. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1-/FOXM1+ Triple Negative Breast Cancer Cells. Mol Pharm. 2019 Mar 29. doi: 10.1021/acs.molpharmaceut.8b01065. [Epub ahead of print]
PubMed ID: 30883132López-Serrano C, Santos-Nogueira E, Francos-Quijorna I, Coll-Miró M, Chun J, López-Vales R. Lysophosphatidic acid receptor type 2 activation contributes to secondary damage after spinal cord injury in mice. Brain Behav Immun. 2019 Feb;76:258-267. doi: 10.1016/j.bbi.2018.12.007. Epub 2018 Dec 11.
PubMed ID: 30550929Yanagida K, Igarashi H, Yasuda D, Kobayashi D, Ohto-Nakanishi T, Akahoshi N, Sekiba A, Toyoda T, Ishijima T, Nakai Y, Shojima N, Kubota N, Abe K, Kadowaki T, Ishii S, Shimizu T. The Gα12/13-coupled receptor LPA4 limits proper adipose tissue expansion and remodeling in diet-induced obesity. JCI Insight. 2018 Dec 20;3(24). pii: 97293. doi: 10.1172/jci.insight.97293.
PubMed ID: 30568036Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett. 2019 Feb 1;442:464-474. doi: 10.1016/j.canlet.2018.11.023. Epub 2018 Nov 29.
PubMed ID: 30503552Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, Parrill AL, Tigyi G, Fujiwara Y. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19. doi: 10.1074/jbc.M109.003194. Epub 2009 Apr 14.
PubMed ID: 19366702- Certificate of Analysis (Lot No. 857130C-200MG-A-082 and 5798CNA082)
- Certificate of Analysis (Lot No. 857130C-25MG-A-082 and 5798CJA082)
- Certificate of Analysis (Lot No. 857130P-25MG-A-083 and 5798PJA083)
- Certificate of Analysis (Lot No. 857130P-200MG-A-083 and 5798PNA083)
- Certificate of Analysis (Lot No. 857130P-1G-A-083 and 5798PQA083)
- Certificate of Analysis (Lot No. 857130P-25MG-A-084 and 5798PJA084)
- Certificate of Analysis (Lot No. 857130C-200MG-A-084 and 5798CNA084)
- Certificate of Analysis (Lot No. 857130P-1G-A-084 and 5798PQA084)
- Certificate of Analysis (Lot No. 857130P-1G-A-085 and 5798PQA085)
- Certificate of Analysis (Lot No. 857130P-25MG-A-085 and 5798PJA085)
- Certificate of Analysis (Lot No. 857130C-25MG-A-085 and 5798CJA085)
- Certificate of Analysis (Lot No. 857130P-1G-A-086 and 5798PQA086)
- Certificate of Analysis (Lot No. 857130C-25MG-A-086 and 5798CJA086)
- Certificate of Analysis (Lot No. 857130P-25MG-A-086 and 5798PJA086)
- Certificate of Analysis (Lot No. 857130C-25MG-B-086 and 5798CJB086)
- Certificate of Analysis (Lot No. 857130P-200MG-A-086 and 5798PNA086)
- Certificate of Analysis (Lot No. 857130P-25MG-B-086 and 5798PJB086)
- Certificate of Analysis (Lot No. 857130P-200MG-A-087 and 5798PNA087)
- Certificate of Analysis (Lot No. 857130C-25MG-A-087 and 5798CJA087)
- Certificate of Analysis (Lot No. 857130P-25MG-A-087 and 5798PJA087)
- Certificate of Analysis (Lot No. 857130P-200MG-B-087 and 5798PNB087)
- Certificate of Analysis (Lot No. 857130C-200MG-A-087 and 5798CNA087)
- Certificate of Analysis (Lot No. 857130P-25MG-A-088 and 5798PJA088)
- Certificate of Analysis (Lot No. 857130P-200MG-A-088 and 5798PNA088)
- Certificate of Analysis (Lot No. 857130P-200MG-A-089 and 5798PNA089)
- Certificate of Analysis (Lot No. 857130C-25MG-A-089 and 5798CJA089)
- Certificate of Analysis (Lot No. 857130P-25MG-A-089 and 5798PJA089)
- Certificate of Analysis (Lot No. 857130P-25MG-B-089 and 5798PJB089)
- Certificate of Analysis (Lot No. 857130P-25MG-C-089 and 5798PJC089)
- Certificate of Analysis (Lot No. 857130P-1G-B-091 and 5798PQB091)
- Certificate of Analysis (Lot No. 857130P-25MG-C-090 and 5798PJC090)
- Certificate of Analysis (Lot No. 857130P-1G-A-092 and 5798PQA092)
- Certificate of Analysis (Lot No. 857130C-25MG-A-091 and 5798CJA091)
- Certificate of Analysis (Lot No. 857130P-200MG-A-092 and 5798PNA092)
- Certificate of Analysis (Lot No. 857130C-25MG-B-091 and 5798CJB091)
- Certificate of Analysis (Lot No. 857130P-25MG-B-091 and 5798PJB091)
- Certificate of Analysis (Lot No. 857130P-25MG-A-091 and 5798PJA091)
- Certificate of Analysis (Lot No. 857130C-200MG-A-093 and 5798CNA093)
- Certificate of Analysis (Lot No. 857130C-25MG-D-091 and 5798CJD091)
- Certificate of Analysis (Lot No. 857130P-200MG-A-093 and 5798PNA093)
- Certificate of Analysis (Lot No. 857130P-200MG-B-093 and 5798PNB093)
- Certificate of Analysis (Lot No. 857130P-25MG-A-092 and 5798PJA092)
- Certificate of Analysis (Lot No. 857130P-25MG-A-093 and 5798PJA093)
- Certificate of Analysis (Lot No. 857130P-25MG-B-093 and 5798PJB093)
- Certificate of Analysis (Lot No. 857130P-200MG-C-093 and 5798PNC093)
- Certificate of Analysis (Lot No. 857130C-25MG-A-093 and 5798CJA093)